Abstract
This study examined the immunomodulatory effect of arvanil, a synthetic capsaicin-anandamide hybrid. Arvanil inhibits lymphocyte proliferation and IFN-γ production. The phenotype of activated CD4 + T cells treated with arvanil shows a down-regulation of T cell activation markers such as CD25, HLA-DR and CD134/OX40. Arvanil and anandamide do not induce apoptosis on CD4 + T cells. Arvanil blocks the G1/S phase transition of the cell cycle in stimulated peripheral blood mononuclear cells, inducing activation of p21waf-1/cip-1 and phosphorylation of Akt/PKB. In vivo, arvanil ameliorates experimental autoimmune encephalomyelitis in the SJL/J mouse. Our findings have relevance for the use of arvanil and related compounds as a novel immunotherapeutic approach in the treatment of multiple sclerosis.
Original language | English |
---|---|
Pages (from-to) | 110-119 |
Number of pages | 10 |
Journal | Journal of Neuroimmunology |
Volume | 171 |
Issue number | 1-2 |
DOIs | |
Publication status | Published - Feb 2006 |
Keywords
- Cannabinoids
- EAE
- Multiple sclerosis
- T cells
ASJC Scopus subject areas
- Immunology
- Clinical Neurology
- Immunology and Allergy
- Neurology